{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:43:54Z","timestamp":1790675034871,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T00:00:00Z","timestamp":1355356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s10384-012-0219-3","type":"journal-article","created":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T01:35:16Z","timestamp":1355276116000},"page":"179-184","source":"Crossref","is-referenced-by-count":44,"title":["Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost"],"prefix":"10.1007","volume":"57","author":[{"given":"Rei","family":"Sakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiroaki","family":"Shirato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"219_CR1","doi-asserted-by":"crossref","unstructured":"Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53 Suppl1:S93\u2013105.","DOI":"10.1016\/j.survophthal.2008.08.004"},{"key":"219_CR2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/01.opx.0000141791.16683.4a","volume":"81","author":"LS Peplinski","year":"2004","unstructured":"Peplinski LS, Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81:574\u20137.","journal-title":"Optom Vis Sci"},{"key":"219_CR3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/IOP.0b013e31817d81df","volume":"24","author":"T Filippopoulos","year":"2008","unstructured":"Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008;24:302\u20137.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"219_CR4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1055\/s-2008-1027362","volume":"225","author":"C Tappeiner","year":"2008","unstructured":"Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost\u2014can bimatoprost cause enophthalmos? (in German). Klin Monbl Augenheilkd. 2008;225:443\u20135.","journal-title":"Klin Monbl Augenheilkd"},{"key":"219_CR5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/jop.2009.0019","volume":"25","author":"JC Yam","year":"2009","unstructured":"Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther. 2009;25:471\u20132.","journal-title":"J Ocul Pharmacol Ther"},{"key":"219_CR6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10384-008-0623-x","volume":"53","author":"HK Yang","year":"2009","unstructured":"Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53:176\u20139.","journal-title":"Jpn J Ophthalmol"},{"key":"219_CR7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10384-011-0075-6","volume":"55","author":"M Aihara","year":"2011","unstructured":"Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol. 2011;55:600\u20134.","journal-title":"Jpn J Ophthalmol"},{"key":"219_CR8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10384-010-0904-z","volume":"55","author":"J Park","year":"2011","unstructured":"Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55:22\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"219_CR9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10384-012-0139-2","volume":"56","author":"K Kashiwagi","year":"2012","unstructured":"Kashiwagi K. Efficacy and safety of switching to travoprost\/timolol fixed-combination therapy from latanoprost monotherapy. Jpn J Ophthalmol. 2012;56:339\u201345.","journal-title":"Jpn J Ophthalmol"},{"key":"219_CR10","unstructured":"http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=53240 ."},{"key":"219_CR11","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000391\/WC500044432.pdf ."},{"key":"219_CR12","unstructured":"http:\/\/www.info.pmda.go.jp\/shinyaku\/P200800044\/300237000_22000AMX02366_B101_1.pdf ."},{"key":"219_CR13","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022184Orig1s000SumR.pdf ."},{"key":"219_CR14","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000665\/WC500038204.pdf ."},{"key":"219_CR15","doi-asserted-by":"crossref","first-page":"e-42","DOI":"10.1097\/IOP.0b013e31821d86a5","volume":"28","author":"T Ung","year":"2012","unstructured":"Ung T, Currie ZI. Periocular changes following long-term administration of latanoprost 0.005%. Ophthal Plast Reconstr Surg. 2012;28:e-42\u20134.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"219_CR16","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","volume":"112","author":"R Valk van der","year":"2005","unstructured":"van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177\u201385.","journal-title":"Ophthalmology"},{"key":"219_CR17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ophtha.2009.01.036","volume":"116","author":"JW Cheng","year":"2009","unstructured":"Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009;116:1243\u20139.","journal-title":"Ophthalmology"},{"key":"219_CR18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/15569521003796860","volume":"29","author":"S Aydin","year":"2010","unstructured":"Aydin S, Isikligil I, Teksen YA, Kir E. Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature. Cutan Ocul Toxicol. 2010;29:212\u20136.","journal-title":"Cutan Ocul Toxicol"},{"key":"219_CR19","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/OPX.0b013e3182231202","volume":"88","author":"S Nakakura","year":"2011","unstructured":"Nakakura S, Tabuchi H, Kiuchi Y. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost. Optom Vis Sci. 2011;88:1140\u20134.","journal-title":"Optom Vis Sci"},{"key":"219_CR20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/01676830.2010.527028","volume":"29","author":"A Jayaprakasam","year":"2010","unstructured":"Jayaprakasam A, Ghazi-Nouri S. Periorbital fat atrophy\u2014an unfamiliar side effect of prostaglandin analogues. Orbit. 2010;29:357\u20139.","journal-title":"Orbit"},{"key":"219_CR21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1432-0436.1996.6040203.x","volume":"60","author":"DA Casimir","year":"1996","unstructured":"Casimir DA, Miller CW, Ntambi JM. Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3-L1 cells. Differentiation. 1996;60:203\u201310.","journal-title":"Differentiation"},{"key":"219_CR22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/bbrc.1997.6433","volume":"233","author":"G Serrero","year":"1997","unstructured":"Serrero G, Lepak NM. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun. 1997;233:200\u20132.","journal-title":"Biochem Biophys Res Commun"},{"key":"219_CR23","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1210\/en.137.12.5641","volume":"137","author":"CW Miller","year":"1996","unstructured":"Miller CW, Casimir DA, Ntambi JM. The mechanism of inhibition of 3T3-L1 preadipocyte differentiation by prostaglandin F2alpha. Endocrinology. 1996;137:5641\u201350.","journal-title":"Endocrinology"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-012-0219-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-012-0219-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-012-0219-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T16:20:37Z","timestamp":1559146837000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-012-0219-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,13]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["219"],"URL":"https:\/\/doi.org\/10.1007\/s10384-012-0219-3","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,13]]}}}